Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00888199
Recruitment Status : Unknown
Verified April 2009 by Tensegrity Prosthetics.
Recruitment status was:  Not yet recruiting
First Posted : April 27, 2009
Last Update Posted : April 27, 2009
National Institutes of Health (NIH)
Information provided by:
Tensegrity Prosthetics

April 23, 2009
April 27, 2009
April 27, 2009
January 2010
June 2010   (Final data collection date for primary outcome measure)
  • Change in metabolic cost of transport [ Time Frame: 30 and 60 days after the beginning of the protocol ]
  • Stride time variability [ Time Frame: 30 and 60 days after beginning of protocol ]
Same as current
No Changes Posted
  • Amputee Mobility Predictor Questionnaire [ Time Frame: Beginning and end of protocol ]
  • Actual change in activity as measured by a step counter [ Time Frame: throughout protocol (60 days) ]
Same as current
Not Provided
Not Provided
Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis
Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis
The purpose of this clinical trial is to determine if the experimental Tensegrity prosthetic foot offers a reduction of the amount of oxygen used while walking, if stability is improved over current prosthetic feet, and whether the experimental device actually increases activity in amputees.
Tensegrity Prosthetics' objectives are to test whether the K3 Promoter prosthetic foot affects walking efficiency or stability in trans-tibial unilateral amputees when compared to their current prostheses. The primary objectives are to determine if the experimental foot changes Cost of Transport (ml O2/kg/meter) or Stride Time Variability compared to an amputee's current prosthesis. Cost of Transport is an indicator of metabolic efficiency and Stride Time Variability indicates how likely a person is to fall. Oxygen consumption and stride time will be collected on a treadmill at the Gait and Motion Lab at the University of Colorado in Boulder.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Device: Experimental prosthetic foot (K3 Promoter)
Experimental prosthetic foot
  • Experimental: Congenital/Traumatic
    Individuals who were born with a limb deficiency or who have had a traumatic amputation.
    Intervention: Device: Experimental prosthetic foot (K3 Promoter)
  • Experimental: Dysvascular/Diabetic
    Individuals who have had an amputation as a result of vascular disease.
    Intervention: Device: Experimental prosthetic foot (K3 Promoter)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
June 2010
June 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. K2 or K3 classification based on current prosthetic device.
  2. Males and females ≥ 18 years of age
  3. Willing and able to sign informed consent
  4. Able to read, write, and speak English
  5. Documented to have a unilateral trans-tibial amputation
  6. Actively utilizing a definitive prosthesis for at least 12 months
  7. Utilizing current prosthetic foot for at least 3 months
  8. Cognitively functional, in the opinion of the prosthetists'
  9. Able to maintain a good gait on their existing limb for approximately 45 minutes
  10. have a healthy residual limb in good condition
  11. have a socket with a good, trouble-free fit on their residual limb

Exclusion Criteria:

  1. Significant ulcers or infections associated with a compromised circulation of the other lower limb
  2. Intermittent Claudication or Critical Leg Ischemia in the non-amputated leg
  3. K0, K1or K4 Classification
  4. Irreducible, pronounced knee or hip flexion contractures
  5. Bilateral amputations
  6. Use of a walker for ambulation
  7. Severe arthritis that would limit the ability to stand without pain or discomfort or the subject's ability to ambulate is limited by symptoms other than the prothesis (e.g., shortness of breath, fatigue, angina, arthritis, etc.). If, in the opinion of the investigator, the subject were to improve their ability to ambulate from the K3 Promoter to the extent that his or her walking would then be limited by a symptom other than the prothesis, the subject should not be enrolled
  8. Any other clinically significant medical or psychiatric condition that in the opinion of the Investigator could impact the subject's ability to successfully complete this trial
  9. Advanced neurologic disorder
  10. Severe congestive heart failure, angina pectoris, or obstructive pulmonary disease
  11. Use of medication that causes impaired balance or judgment
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Jerome Rifkin/CEO & CTO, Tensegrity Prosthetics
Tensegrity Prosthetics
National Institutes of Health (NIH)
Principal Investigator: Jerome Rifkin, MS ME Tensegrity Prosthetics
Tensegrity Prosthetics
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP